Hedgehog blockade in steroid-refractory sclerotic chronic graft-versus-host disease

Br J Haematol. 2021 Oct;195(2):e120-e122. doi: 10.1111/bjh.17657. Epub 2021 Jun 17.

Authors

Vedran Radojcic^{1

2}, Maria Pletneva³, Catherine J Lee^{1

2}, Sanja Ivcevic², Stefanie Sarantopoulos⁴, Daniel Couriel^{1

2}

Affiliations

¹ Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
² Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
³ Department of Pathology, University of Utah, Salt Lake City, UT, USA.
⁴ Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University Medical Center, Durham, England.

No abstract available

Publication types

Clinical Trial
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Anilides / administration & dosage
Anilides / adverse effects
Anilides / pharmacology*
Anilides / therapeutic use
Biopsy
Chronic Disease
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / pathology
Hedgehog Proteins / antagonists & inhibitors*
Hedgehog Proteins / pharmacology
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Pyridines / administration & dosage
Pyridines / adverse effects
Pyridines / pharmacology*
Pyridines / therapeutic use
Sclerosis / diagnosis
Skin / pathology
Steroids / therapeutic use

Substances

Anilides
Hedgehog Proteins
HhAntag691
Pyridines
Steroids

Grants and funding